These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. A Lepromatous Leprosy Patient with Permanent Disability. Wang N, Liu H, Zhang F. Am J Trop Med Hyg; 2015 Nov; 93(5):896-898. PubMed ID: 26537774 [No Abstract] [Full Text] [Related]
46. Nerve damage in leprosy. Job CK. Int J Lepr Other Mycobact Dis; 1989 Jun; 57(2):532-9. PubMed ID: 2545801 [No Abstract] [Full Text] [Related]
47. Lepromatous leprosy in an HIV-positive patient in Spain. Moreno-Giménez IC, Valverde F, Rios JI, Logroño C, Rubio FL. J Eur Acad Dermatol Venereol; 2000 Jul; 14(4):290-2. PubMed ID: 11204518 [Abstract] [Full Text] [Related]
48. Histological assessment of dermal nerve damage occurring during multidrug therapy for leprosy. Jain M, Singh N, Bhatia A, Arora VK. Int J Lepr Other Mycobact Dis; 2000 Jun; 68(2):167-71. PubMed ID: 11036497 [Abstract] [Full Text] [Related]
53. [Lucio's phenomenon in a patient with leprosy on Aruba]. Huits RM, Oskam L, van Raalte JA. Ned Tijdschr Geneeskd; 2012 Jun; 156(14):A4285. PubMed ID: 22475236 [Abstract] [Full Text] [Related]
57. Borderline lepromatous leprosy presenting as a single cutaneous plaque. Armour KS, Scolyer RA, Barnetson RS. Australas J Dermatol; 2005 Aug; 46(3):181-3. PubMed ID: 16008652 [Abstract] [Full Text] [Related]
58. A challenging case of borderline lepromatous leprosy non-responsive to WHO-MDT: exploring approaches beyond WHO-MDT. Sharma A, Parkhi M, Chhabra S, Narang T, Handa S, Dogra S. Trans R Soc Trop Med Hyg; 2024 Jul 05; 118(7):477-479. PubMed ID: 38695179 [Abstract] [Full Text] [Related]
59. Trials of daily, long-term minocycline and rifampin or clarithromycin and rifampin in the treatment of borderline lepromatous and lepromatous leprosy. Rea TH. Int J Lepr Other Mycobact Dis; 2000 Jun 05; 68(2):129-35. PubMed ID: 11036492 [Abstract] [Full Text] [Related]